Webinar Description:
Biomarkers are a critical aspect of bioanalytical testing, as they provide a vast amount of information, from the effects of a drug on the subject to determining the drug’s mechanism of action and the correct dose for a patient. When developing a biomarker, it is important to understand the context of use to determine the level of development required. The level of development can be as simple as kit implementation or as in-depth as a fit-for-purpose validation. Understanding a study’s needs will help guide the level of development and determine the appropriate platform and assay.
Speaker:
Lindsay Rutherford, Ph.D., Scientific Advisor, Biopharma Services
Lindsay is currently a Scientific Advisor at KCAS Bio, supporting Ligand Binding Assay (LBA) services. Lindsay has over 15 years of experience in assay development and previously worked at ICON overseeing the Large Molecule Method development team. Prior to her CRO work, Lindsay spent 10 years in the diagnostic and drug development space. She received her Ph.D. in Chemistry at the University of Arkansas and works out of the Kansas City area.
What Will You Learn:
- What a pharmacodynamic (PD) marker is
- Bioanalytical considerations of biomarker development depending on the context of use
- The difference between the level of development in terms of qualification and validation
- Types of methods/platforms in the LBA space and considerations for sample type and size requirements, and availability of critical reagents/kits
- What off-the-shelf biomarker assays are and how they are used
Whom This May Interest:
- Individuals interested in learning more about biomarkers
- Individuals who are looking to outsource bioanalytical studies
- Individuals who develop and validate biomarker assays
Don’t Miss Out – Get Access Today!
To gain exclusive access to the webinar, complete the form below.